Sanofi ADS has moved -0.7% over the last year, and the S&P 500 logged a change of 11.9% SNY has an average analyst rating of ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

The firms are planning two clinical trials of the anti-CTLA-4 agent muzastotug in colorectal cancer and in solid tumors.

Adagene Inc. (NASDAQ:ADAG) saw its shares rise by 6.1% on Tuesday after the biotech firm revealed a strategic investment deal ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as ...